Processa Pharmaceuticals Stock Performance
PCSA Stock | USD 1.60 0.07 4.58% |
The company holds a Beta of 7.64, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Processa Pharmaceuticals will likely underperform. Processa Pharmaceuticals has an expected return of -1.46%. Please make sure to check Processa Pharmaceuticals expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Processa Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Processa Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:20 | Dividend Date 2019-12-23 | Last Split Date 2024-01-22 |
1 | Insider Buying Processa Pharmaceuticals, Inc. Director Purchases 8,000 Shares of Stock | 02/01/2024 |
2 | Processa Pharmaceuticals Inc Up 2.99 percent in Premarket Trading - InvestorsObserver | 02/02/2024 |
3 | Processa Pharmaceuticals regains Nasdaq compliance | 02/06/2024 |
4 | Purchase by David Young of 21000 shares of Processa Pharmaceuticals | 02/08/2024 |
5 | What is the Markets View on Processa Pharmaceuticals Inc Stocks Price and Volume Trends Friday - InvestorsObserver | 02/09/2024 |
6 | Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference | 02/14/2024 |
7 | Acquisition by David Young of 8572 shares of Processa Pharmaceuticals subject to Rule 16b-3 | 02/21/2024 |
8 | Processa Pharmaceuticals Speculative Buy Rating Reiterated at Benchmark | 03/06/2024 |
9 | Acquisition by Ng George K of 400000 shares of Processa Pharmaceuticals subject to Rule 16b-3 | 03/08/2024 |
10 | Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting | 03/25/2024 |
11 | Processa Pharmaceuticals Stock Price Down 1.7 percent - Defense World | 04/04/2024 |
12 | Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial | 04/11/2024 |
Begin Period Cash Flow | 6.5 M |
Processa |
Processa Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 510.00 in Processa Pharmaceuticals on January 25, 2024 and sell it today you would lose (350.00) from holding Processa Pharmaceuticals or give up 68.63% of portfolio value over 90 days. Processa Pharmaceuticals is currently does not generate positive expected returns and assumes 8.3288% risk (volatility on return distribution) over the 90 days horizon. In different words, 73% of stocks are less volatile than Processa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Processa Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Processa Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Processa Pharmaceuticals, and traders can use it to determine the average amount a Processa Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1751
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | PCSA |
Estimated Market Risk
8.33 actual daily | 73 73% of assets are less volatile |
Expected Return
-1.46 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Processa Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Processa Pharmaceuticals by adding Processa Pharmaceuticals to a well-diversified portfolio.
Processa Pharmaceuticals Fundamentals Growth
Processa Stock prices reflect investors' perceptions of the future prospects and financial health of Processa Pharmaceuticals, and Processa Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Processa Stock performance.
Return On Equity | -1.79 | ||||
Return On Asset | -0.99 | ||||
Current Valuation | (185.99 K) | ||||
Shares Outstanding | 2.86 M | ||||
Price To Book | 0.96 X | ||||
EBITDA | (11.46 M) | ||||
Net Income | (11.12 M) | ||||
Cash And Equivalents | 12.06 M | ||||
Cash Per Share | 0.76 X | ||||
Total Debt | 150.55 K | ||||
Debt To Equity | 0 % | ||||
Current Ratio | 8.89 X | ||||
Book Value Per Share | 3.88 X | ||||
Cash Flow From Operations | (8.06 M) | ||||
Earnings Per Share | (8.48) X | ||||
Market Capitalization | 4.37 M | ||||
Total Asset | 5.79 M | ||||
Retained Earnings | (75.37 M) | ||||
Working Capital | 4.9 M | ||||
About Processa Pharmaceuticals Performance
To evaluate Processa Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Processa Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Processa Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Processa Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Processa's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 643.99 | 344.59 | |
Return On Tangible Assets | (1.92) | (2.02) | |
Return On Capital Employed | (2.27) | (2.38) | |
Return On Assets | (1.92) | (2.02) | |
Return On Equity | (2.23) | (2.34) |
Things to note about Processa Pharmaceuticals performance evaluation
Checking the ongoing alerts about Processa Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Processa Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Processa Pharmaceuticals generated a negative expected return over the last 90 days | |
Processa Pharmaceuticals has high historical volatility and very poor performance | |
Processa Pharmaceuticals may become a speculative penny stock | |
Processa Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (11.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Processa Pharmaceuticals currently holds about 12.06 M in cash with (8.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
Processa Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
Latest headline from finance.yahoo.com: Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial |
- Analyzing Processa Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Processa Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Processa Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Processa Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Processa Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Processa Pharmaceuticals' stock. These opinions can provide insight into Processa Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Processa Stock analysis
When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Processa Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.48) | Return On Assets (0.99) | Return On Equity (1.79) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.